The partnership aims to advance pharmaceutical and life sciences ventures originating from BIRAD- Bar-Ilan University, turning laboratory discoveries into solutions that address unmet medical needs.
(RTTNews) - Hadasit Medical Research Services and Development and BIRAD - Research & Development Company Ltd. have entered into the research and license agreement with Immix BioPharma for the ...
The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy at ...
Cost-effectiveness of letrozole and anastrozole as adjuvant therapy for hormone receptor positive early breast cancer in postmenopausal women No significant financial relationships to disclose. This ...
Accuracy and upgrade rates of stereotactic vacuum-assisted breast biopsy: Impact of number of core samples taken on malignancy underestimation rates. Background: The shift from the use of BrMR for ...
HAIFA, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company that transforms cells into solutions, today announced ...
(MENAFN- PR Newswire) The partnership primarily targets the pharmaceutical and life sciences sectors, with a focus on advancing commercialization and technology transfer, bolstering BIRAD's efforts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results